GLP-1 vs. GIP: how Zepbound’s dual action works

If you have been researching GLP-1 medications for weight loss, you have probably noticed that Zepbound is described differently from Wegovy. Wegovy is a GLP-1 receptor agonist. Zepbound is a dual GLP-1/GIP receptor agonist. That distinction matters — and understanding it can help you have a more informed conversation with your clinician about which medication may be right for you.

This article explains the science behind both hormones, how Zepbound activates them simultaneously, and what the clinical evidence says about dual-action treatment for weight loss.

Two hormones, one medication

Zepbound (tirzepatide) is unique among FDA-approved weight loss medications because it targets two distinct hormone receptors: GLP-1 and GIP. Most other medications in this class — including Wegovy (semaglutide) and Saxenda (liraglutide) — target only GLP-1.

Both GLP-1 and GIP belong to a family of hormones called incretins. Incretins are released by your gut after you eat, and they play important roles in regulating blood sugar, insulin release, appetite, and how your body processes nutrients. By activating both pathways, tirzepatide produces effects that neither hormone could achieve alone.

What is GLP-1?

GLP-1 stands for glucagon-like peptide-1. It is an incretin hormone released by L-cells in your small intestine after you eat. In a healthy body, GLP-1 does several things:

• Signals satiety to the brain. GLP-1 acts on receptors in the hypothalamus and brainstem to reduce hunger and increase the feeling of fullness after a meal.
• Slows gastric emptying. Food moves from your stomach to your intestines more slowly, which prolongs the feeling of fullness and reduces the urge to eat again quickly.
• Stimulates insulin release. GLP-1 triggers glucose-dependent insulin secretion from the pancreas, helping to lower blood sugar after meals.
• Suppresses glucagon. It reduces the release of glucagon, a hormone that raises blood sugar, creating a more balanced glucose response.

Naturally occurring GLP-1 is broken down within minutes by an enzyme called DPP-4. Medications like semaglutide (Wegovy) are engineered to resist this breakdown, allowing them to remain active in the body for days rather than minutes. This is why Wegovy is a once-weekly injection — the modified molecule sustains GLP-1 receptor activation throughout the week.

What is GIP?

GIP stands for glucose-dependent insulinotropic polypeptide. It is the other major incretin hormone, released by K-cells in the upper small intestine after eating. For decades, GIP received less attention than GLP-1 in weight management research, but that has changed significantly with the development of tirzepatide.

GIP has distinct effects that complement — but do not simply duplicate — what GLP-1 does:

• Effects on fat tissue. GIP receptors are expressed on adipose (fat) tissue. GIP signaling influences how fat cells store and release energy, and may improve the body’s ability to metabolize fat more efficiently.
• Insulin sensitivity. Like GLP-1, GIP stimulates insulin release from the pancreas. But GIP also appears to improve insulin sensitivity in peripheral tissues, meaning your body may use insulin more effectively.
• Appetite regulation through different brain pathways. While GLP-1 acts primarily on the hypothalamus and brainstem, GIP activates receptors in overlapping but distinct brain regions. This means the two hormones may produce complementary satiety signals rather than redundant ones.
• Potential protective effects. Emerging research suggests GIP may have beneficial effects on bone density and cardiovascular markers, though more research is needed in these areas.

How dual action works

Tirzepatide is a single molecule that activates both GLP-1 and GIP receptors simultaneously. It is not two separate drugs combined — it is one engineered peptide designed to bind to both receptor types. This is an important distinction because the dual activation creates effects that are more than additive.

Here is how the two pathways complement each other:

The result is a medication that addresses weight loss through multiple biological pathways simultaneously. The appetite suppression comes from both GLP-1 and GIP acting on the brain. The metabolic improvements come from complementary effects on insulin, fat tissue, and energy processing. This multi-pathway approach may explain the clinical results we see in trials.

Clinical evidence

The most significant clinical evidence for tirzepatide’s efficacy comes from the SURMOUNT trial program. These were large, randomized, double-blind, placebo-controlled trials — the gold standard for clinical evidence.

Key findings from the SURMOUNT trials:

• Participants on the highest dose of tirzepatide (15mg) achieved an average weight loss of approximately 20.9% of their body weight over 72 weeks.
• Even the lowest dose (5mg) produced an average weight loss of approximately 15% — comparable to the results seen with semaglutide in the STEP trials.
• A significant proportion of participants achieved clinically meaningful weight loss thresholds (at least 5%, 10%, 15%, and 20% of body weight).

For comparison, the STEP trials for semaglutide (Wegovy) at the 2.4mg dose showed an average weight loss of approximately 15% of body weight over 68 weeks.

That said, the magnitude of the difference — approximately 20.9% average weight loss with tirzepatide versus approximately 15% with semaglutide — is large enough that many clinicians and researchers consider it clinically meaningful. The dual mechanism is the leading hypothesis for why tirzepatide may produce greater weight loss.

Does dual action mean more side effects?

This is one of the most common questions patients ask, and it is a reasonable one. If a medication activates two receptor pathways instead of one, you might expect it to cause more side effects. But the clinical data tells a more nuanced story.

The side effect profiles of Zepbound and Wegovy are broadly similar. The most common adverse effects for both medications are gastrointestinal:

• Nausea — the most frequently reported side effect for both medications
• Diarrhea — common during dose titration
• Vomiting — more common at higher doses
• Constipation — reported by some patients on both medications
• Decreased appetite — technically a side effect, though often a desired one

In the SURMOUNT trials, the rates of GI side effects with tirzepatide were comparable to the rates seen with semaglutide in the STEP trials. Dual action does not appear to double the side effect burden. The GIP pathway may even help moderate some GI effects, though more research is needed to confirm this.

Which is right for you?

This is a clinical decision, not a marketing one. The fact that tirzepatide targets two receptors does not automatically make it the better choice for every patient. Several factors go into determining which medication is right for you:

• Insurance coverage. Coverage for Wegovy and Zepbound varies significantly by insurer and plan. One medication may be covered while the other is not, or one may require prior authorization while the other does not. This practical consideration often drives the initial choice.
• Individual response. Some patients respond exceptionally well to semaglutide and achieve all of their weight loss goals on Wegovy alone. Others may benefit from the dual mechanism of tirzepatide. There is no way to predict your individual response in advance.
• Medical history. Your overall health profile, including any history of pancreatitis, thyroid conditions, or type 2 diabetes, will influence which medication your clinician recommends. Both medications have similar contraindications, but subtle differences in your history may favor one over the other.
• Side effect tolerance. If you have tried one medication and experienced intolerable side effects, switching to the other is a reasonable clinical strategy. Different patients tolerate different medications differently.
• Treatment goals. Your target weight loss, timeline, and overall health objectives all factor into the decision. A patient who needs 10% weight loss may not need a dual-agonist medication, while a patient targeting 20% or more may benefit from it.

Understanding the science behind these medications is valuable — it helps you ask better questions and participate more actively in your care. But the science is only one input. Your clinician integrates that science with your specific medical situation to make a recommendation that is right for you, specifically.

Important safety information: Zepbound carries a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. It is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Discuss your full medical history with your clinician before starting treatment.

Medication labeling reminder: Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes only. For weight management, the FDA-approved options are Wegovy (semaglutide) and Zepbound (tirzepatide).

Boxed warning — thyroid C-cell tumors: GLP-1-based medications (including semaglutide and tirzepatide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. These medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.

The PEAK Clinical Team

PEAK Wellness & Aesthetics

Evidence-based guidance from our board-certified clinicians specializing in medical weight loss and obesity medicine.